002603 以岭药业
午间休市 10-15 11:30:00
资讯
新帖
简况
以岭药业荣获阿里健康大药房“2026年度最佳伙伴”
证券之星 · 10-08
以岭药业荣获阿里健康大药房“2026年度最佳伙伴”
源头质控再加码！以岭药业万亩苦杏仁野生基地通过GAP延伸检查
证券之星 · 09-29
源头质控再加码！以岭药业万亩苦杏仁野生基地通过GAP延伸检查
股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》
证券之星 · 09-23
股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》
以岭药业(002603.SZ)孙公司收到阿那曲唑原料药欧洲CEP证书
智通财经 · 09-21
以岭药业(002603.SZ)孙公司收到阿那曲唑原料药欧洲CEP证书
以岭药业（002603）披露实际控制人部分股份质押展期公告，9月14日股价上涨1.25%
证券之星 · 09-14
以岭药业（002603）披露实际控制人部分股份质押展期公告，9月14日股价上涨1.25%
股市必读：以岭药业新发布《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》
证券之星 · 09-14
股市必读：以岭药业新发布《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》
以岭药业（002603）披露将参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会，9月10日股价下跌1.78%
证券之星 · 09-10
以岭药业（002603）披露将参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会，9月10日股价下跌1.78%
以岭药业(002603)：创新成果持续兑现 关注基药目录落地
证券之星 · 09-08
以岭药业(002603)：创新成果持续兑现 关注基药目录落地
以岭药业入选2026年中国中成药出海领航企业榜10强
证券之星 · 09-04
以岭药业入选2026年中国中成药出海领航企业榜10强
双奖加冕！以岭药业斩获”第七届全景投资者关系金奖“两项荣誉
证券之星 · 09-02
双奖加冕！以岭药业斩获”第七届全景投资者关系金奖“两项荣誉
以岭药业：8月29日召开业绩说明会，华创证券、国盛证券等多家机构参与
证券之星 · 08-31
以岭药业：8月29日召开业绩说明会，华创证券、国盛证券等多家机构参与
股市必读：以岭药业新发布《2026年半年度报告摘要》
证券之星 · 08-31
股市必读：以岭药业新发布《2026年半年度报告摘要》
以岭药业2026上半年营收超40亿元，净利润7.57亿元
证券之星 · 08-28
以岭药业2026上半年营收超40亿元，净利润7.57亿元
股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》
证券之星 · 08-28
股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》
以岭药业最新公告：全资孙公司获来曲唑原料药欧洲CEP证书
证券之星 · 08-26
以岭药业最新公告：全资孙公司获来曲唑原料药欧洲CEP证书
8月20日以岭药业涨5.27%，中药ETF汇添富基金重仓该股
证券之星 · 08-20
8月20日以岭药业涨5.27%，中药ETF汇添富基金重仓该股
抗衰老产业持续受到关注：八子补肾入选《中国抗衰老产业年度报告》，以岭药业核心价值凸显
证券之星 · 08-17
抗衰老产业持续受到关注：八子补肾入选《中国抗衰老产业年度报告》，以岭药业核心价值凸显
股市必读：以岭药业新发布《关于化药创新药LB220-D08缓释片药物临床试验申请获得受理的公告》
证券之星 · 08-14
股市必读：以岭药业新发布《关于化药创新药LB220-D08缓释片药物临床试验申请获得受理的公告》
以岭药业(002603.SZ)：化药创新药“LB220-D08缓释片”药物临床试验申请获得受理
智通财经 · 08-12
以岭药业(002603.SZ)：化药创新药“LB220-D08缓释片”药物临床试验申请获得受理
以岭药业：未来将更加重视现金分红
证券之星 · 08-05
以岭药业：未来将更加重视现金分红
加载更多
公司概况
公司名称：
石家庄以岭药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-07-28
主营业务：
石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是专利中药产品。公司获得了国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。
发行价格：
34.56
{"stockData":{"symbol":"002603","market":"SZ","secType":"STK","nameCN":"以岭药业","latestPrice":15,"timestamp":1792036263000,"preClose":15.07,"halted":0,"volume":8362500,"delay":0,"changeRate":-0.0046,"floatShares":1376000000,"shares":1671000000,"eps":0.8232,"marketStatus":"午间休市","change":-0.07,"latestTime":"10-15 11:30:00","open":14.92,"high":15.21,"low":14.81,"amount":126000000,"amplitude":0.0265,"askPrice":15.01,"askSize":380,"bidPrice":15,"bidSize":10,"shortable":0,"etf":0,"ttmEps":0.8232,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792040400000},"marketStatusCode":3,"adr":0,"adjPreClose":15.07,"symbolType":"stock","openAndCloseTimeList":[[1792027800000,1792035000000],[1792040400000,1792047600000]],"highLimit":16.58,"lowLimit":13.56,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1670705376,"isCdr":false,"pbRate":2.31,"roa":"--","peRate":18.221574,"roe":"6.66%","epsLYR":0.77,"committee":0.276276,"marketValue":25061000000,"turnoverRate":0.0061,"status":1,"floatMarketCap":20644000000},"requestUrl":"/m/hq/s/002603","defaultTab":"news","newsList":[{"id":"2673731970","title":"以岭药业荣获阿里健康大药房“2026年度最佳伙伴”","url":"https://stock-news.laohu8.com/highlight/detail?id=2673731970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673731970?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:55","pubTimestamp":1791453308,"startTime":"0","endTime":"0","summary":"2026年9月16日，阿里健康大药房十周年庆典举行，以岭药业获颁“2026年度最佳伙伴”奖。在阿里健康大药房渠道，以岭药业凭借稳定的产品供给和良好的用户口碑，成为平台发展过程中的重要合作伙伴。此次获评“2026年度最佳伙伴”，体现了平台对以岭药业合作价值与双方共建成果的认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026100800024302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HK0000165453.HKD","BK1591","002603","BK0188","BK1615","BK1584","00241","BK1501","BK1515","BK1617","BK1589","BK1571","BK0239","BK1142","BK1610","BK1502","BK0046","BK1189","BK1247","BK0097","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671729781","title":"源头质控再加码！以岭药业万亩苦杏仁野生基地通过GAP延伸检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2671729781","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671729781?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:44","pubTimestamp":1790671447,"startTime":"0","endTime":"0","summary":"9月24日，河北省药品监督管理局发布《中药材GAP延伸检查结果公告》，以岭药业苦杏仁野生基地通过河北省药监局组织的GAP延伸检查，综合评定符合要求。截至目前，以岭药业已在全国已在全国20余个省区，创建60余个规模化、标准化中药材种养殖基地。连翘、金银花等八个品种已通过了GAP延伸检查，泽泻、土元等六个品种通过了“三无一全”现场核查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026092900027367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","BK0046","BK0188","BK0042","002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669292121","title":"股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669292121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669292121?lang=zh_cn&edition=full","pubTime":"2026-09-23 02:00","pubTimestamp":1790100050,"startTime":"0","endTime":"0","summary":"公司公告汇总关于全资孙公司收到化学原料药欧洲CEP证书的公告石家庄以岭药业股份有限公司全资孙公司万洋衡水制药有限公司收到欧洲药品质量管理局签发的阿那曲唑原料药欧洲药典适用性证书，证书编号CEP-2026-059-Rev 00。阿那曲唑为非甾体类芳香化酶抑制剂，用于绝经后激素受体阳性乳腺癌患者的治疗。此次获证表明该原料药质量获欧洲规范市场认可，具备进入欧盟及承认CEP证书其他国家市场的资质。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300002431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0097","BK0046","BK0188","BK0042","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669915136","title":"以岭药业(002603.SZ)孙公司收到阿那曲唑原料药欧洲CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2669915136","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669915136?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:00","pubTimestamp":1789981240,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，近日，公司全资孙公司万洋衡水制药有限公司(简称“衡水万洋”)收到欧洲药品质量管理局(EDQM)签发的阿那曲唑原料药的欧洲药典适用性证书(简称“CEP证书”)。据悉，阿那曲唑(Anastrozole)是一种广泛应用于治疗雌激素相关肿瘤的药物。此次衡水万洋获得阿那曲唑CEP证书，表明欧洲规范市场对该原料药质量的认可和肯定，标志着该产品具备以原料药形式进入欧盟及承认CEP证书的其他市场的资质，为公司进一步拓展国际市场带来积极影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"以岭药业(002603.SZ)孙公司收到阿那曲唑原料药欧洲CEP证书","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","BK0239","002603","BK0046","BK0097","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667652329","title":"以岭药业（002603）披露实际控制人部分股份质押展期公告，9月14日股价上涨1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667652329","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667652329?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:39","pubTimestamp":1789378776,"startTime":"0","endTime":"0","summary":"公司近日披露《关于实际控制人部分股份质押展期的公告》。公告显示，石家庄以岭药业股份有限公司于2026年9月11日接到实际控制人吴相君通知，其持有的15,000,000股公司股份办理了质押展期，占其所持股份比例4.31%，占公司总股本比例0.90%，质押用途为融资，质权人为中信证券股份有限公司，展期后到期日为2027年9月18日。吴相君资信状况良好，具备资金偿还能力，质押风险可控。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400023598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0042","BK0046","002603","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667680339","title":"股市必读：以岭药业新发布《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667680339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667680339?lang=zh_cn&edition=full","pubTime":"2026-09-14 01:23","pubTimestamp":1789320193,"startTime":"0","endTime":"0","summary":"公司公告汇总：以岭药业将于9月16日15:30–17:00参加河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会。关于实际控制人部分股份质押展期的公告石家庄以岭药业股份有限公司于2026年9月11日接到实际控制人吴相君通知，其持有的15,000,000股公司股份办理了质押展期，占其所持股份比例4.31%，占公司总股本比例0.90%，质押用途为融资，质权人为中信证券股份有限公司，展期后到期日为2027年9月18日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002603","BK0097","BK0188","BK0042","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666447591","title":"以岭药业（002603）披露将参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会，9月10日股价下跌1.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666447591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666447591?lang=zh_cn&edition=full","pubTime":"2026-09-10 22:25","pubTimestamp":1789050318,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，以岭药业报收于15.42元，较前一交易日下跌1.78%，最新总市值为257.62亿元。近日，以岭药业披露《关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会的公告》。公告显示，公司将于2026年9月16日15:30-17:00通过网络远程方式参加由河北上市公司协会、河北资本市场之家与深圳市全景网络有限公司联合举办的“2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报集体业绩说明会”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000042169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0097","BK0046","BK0188","BK0042","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665934600","title":"以岭药业(002603)：创新成果持续兑现 关注基药目录落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2665934600","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665934600?lang=zh_cn&edition=full","pubTime":"2026-09-08 10:08","pubTimestamp":1788833288,"startTime":"0","endTime":"0","summary":"8 月28 日，公司发布2026 年半年度报告。展望26H2：1)看好心脑血管品类持续恢复；2)呼吸系统品类渠道健康，持续推广应用场景；3)研发管线成果持续兑现，新品上市贡献新增量；4)院内政策影响有望边际减弱，收入、利润有望持续改善。创新稳步推进，看好创新成果落地截至26H1，公司拥有专利中药创新药17 个，覆盖临床8 个系统疾病，其中12 个品种进入国家医保目录，6 个品种进入国家基本药物目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026090800009963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0042","BK0239","BK0097","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664335727","title":"以岭药业入选2026年中国中成药出海领航企业榜10强","url":"https://stock-news.laohu8.com/highlight/detail?id=2664335727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664335727?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:19","pubTimestamp":1788517198,"startTime":"0","endTime":"0","summary":"以岭药业凭借卓越的国际化战略与科研实力，以88.53的金榜指数位列榜单第二名，彰显了其在中医药出海领域的领航地位。据以岭药业2026年半年报显示，在国际化方面，以岭药业走出了一条“理论出海+产品输出+学术推广”三位一体的国际化路径。截至目前，以岭药业专利中药已在全球50多个国家和地区注册销售，覆盖东南亚、北美、欧洲、非洲等区域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026090400034343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","002603","BK0042","BK0097","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664813198","title":"双奖加冕！以岭药业斩获”第七届全景投资者关系金奖“两项荣誉","url":"https://stock-news.laohu8.com/highlight/detail?id=2664813198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664813198?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:22","pubTimestamp":1788344565,"startTime":"0","endTime":"0","summary":"8月28日，“中国上市公司投资者关系年度盛典”在雄安新区隆重举行，现场正式揭晓了“第七届全景投资者关系金奖”获奖名单。自上市以来，以岭药业始终坚持“真实、准确、完整”的信息披露原则，持续深耕信息披露与投资者关系工作。吴瑞作为以岭药业的董事会秘书，在公司治理、信息发布、投资者关系管理等方面表现突出，获得了评审团和资本市场的高度认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026090200035097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0042","BK0097","002603","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663052870","title":"以岭药业：8月29日召开业绩说明会，华创证券、国盛证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2663052870","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663052870?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:04","pubTimestamp":1788181469,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年8月31日以岭药业发布公告称公司于2026年8月29日召开业绩说明会，华创证券、国盛证券、长城证券、华源证券、华安证券、中邮证券、长江证券、国金证券、投资机构、国联民生证券、中信建投证券、中金公司、国投证券、开源证券、兴业证券、国泰海通证券、华泰证券参与。今年，苯胺洛芬注射液已获批上市，已进入商业化阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100034829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0188","161027","002670","BK0042","BK0052","BK0097","BK0046","BK0239","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663504783","title":"股市必读：以岭药业新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663504783","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663504783?lang=zh_cn&edition=full","pubTime":"2026-08-31 04:03","pubTimestamp":1788120193,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，以岭药业报收于16.18元，下跌0.43%，换手率0.93%，成交量12.81万手，成交额2.07亿元。股本股东变化股东户数变动截至2026年6月30日公司股东户数为14.0万户，较3月31日减少7962.0户，减幅为5.38%；户均持股数量由上期的1.13万股增加至1.19万股，户均持股市值为17.9万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0188","BK0046","002603","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662006439","title":"以岭药业2026上半年营收超40亿元，净利润7.57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662006439","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662006439?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:33","pubTimestamp":1787913221,"startTime":"0","endTime":"0","summary":"8月28日晚间，以岭药业披露2026年半年报显示，公司上半年实现营业收入40.75亿元，同比增长0.86%；归属于上市公司股东的净利润达7.57亿元，同比增长13.28%；经营活动产生的现金流量净额为11.80亿元，同比增长41.79%。以岭药业2026年半年报显示，公司持续的高研发投入开发更多创新产品，产品管线丰富优势显著，在提高经营收入的同时，利润和现金流持续改善，验证了公司高质量发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026082800043604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750037","title":"股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750037","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662750037?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:29","pubTimestamp":1787880593,"startTime":"0","endTime":"0","summary":"公司公告汇总关于全资孙公司收到化学原料药欧洲CEP证书的公告石家庄以岭药业股份有限公司全资孙公司万洋衡水制药有限公司收到欧洲药品质量管理局签发的来曲唑原料药欧洲药典适用性证书，证书编号CEP-2026-058-Rev 00。来曲唑是一种非甾体类芳香化酶抑制剂，用于绝经后激素受体阳性乳腺癌的辅助治疗及晚期乳腺癌治疗。获得CEP证书表明该原料药质量获欧洲规范市场认可，具备进入欧盟及承认CEP证书其他市场的资质。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800017019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","002603","BK0046","BK0188","BK0097","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662914667","title":"以岭药业最新公告：全资孙公司获来曲唑原料药欧洲CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2662914667","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662914667?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:18","pubTimestamp":1787735939,"startTime":"0","endTime":"0","summary":"以岭药业(002603.SZ)公告称，公司全资孙公司万洋衡水制药有限公司收到欧洲药品质量管理局签发的来曲唑原料药欧洲药典适用性证书。该证书表明来曲唑原料药获欧盟市场准入资质，有助于公司拓展国际市场，但药品生产销售存在不确定性，投资者需注意风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600038202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0042","BK0097","BK0239","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660240225","title":"8月20日以岭药业涨5.27%，中药ETF汇添富基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660240225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660240225?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:40","pubTimestamp":1787215249,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日以岭药业涨5.27%，收盘报17.38元，换手率4.07%，成交量56.05万手，成交额9.67亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为汇添富基金的中药ETF汇添富。中药ETF汇添富目前规模为23.05亿元，最新净值0.9738，较上一交易日下跌0.99%，近一年下跌14.74%。中药ETF汇添富的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["560080","BK0239","BK0188","BK0097","BK0042","002603","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660610596","title":"抗衰老产业持续受到关注：八子补肾入选《中国抗衰老产业年度报告》，以岭药业核心价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2660610596","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660610596?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:30","pubTimestamp":1786926625,"startTime":"0","endTime":"0","summary":"2026年8月15日，由中国民族卫生协会、浙江清华长三角研究院、中国民族卫生协会抗衰老专业委员会共同编写的《中国抗衰老产业年度报告》正式发布。以岭药业八子补肾胶囊相关研究被报告收录，也使中医药抗衰老的证据建设与产业转化再次受到关注。结语八子补肾胶囊被《中国抗衰老产业年度报告》收录，是以岭药业持续深耕抗衰老领域、推进创新研发的一个缩影。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026081700001688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002603","BK0042","BK0239","BK0097","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659694181","title":"股市必读：以岭药业新发布《关于化药创新药LB220-D08缓释片药物临床试验申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659694181","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659694181?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:20","pubTimestamp":1786641659,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，以岭药业报收于17.1元，上涨1.91%，换手率3.09%，成交量42.57万手，成交额7.3亿元。当日关注点交易信息汇总：8月13日主力资金净流入1157.6万元，占总成交额1.59%。公司公告汇总：以岭药业自主研发的1类化学新药LB220-D08缓释片临床试验申请获国家药监局受理。该药为靶向Factor B因子的补体抑制剂，可选择性抑制补体旁路途径，抑制毒素生成及膜攻击复合物形成，同时保留凝集素和经典途径功能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400000866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","BK0239","BK0188","159992","002603","BK0042","BK0046","BK0097","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978437","title":"以岭药业(002603.SZ)：化药创新药“LB220-D08缓释片”药物临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978437","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658978437?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:00","pubTimestamp":1786525244,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，该药物名称：“LB220-D08缓释片”。LB220-D08为公司自主研发的全新小分子化学药物，是公司具有独立知识产权的1类化学新药。本品为靶向FactorB因子的补体抑制剂。通过靶向抑制B因子，本品可选择性抑制旁路途径，阻止C3转化酶的活化，从而抑制C3a、C5a等毒素的生成以及C5转化酶和膜攻击复合物(MAC，C5b-9)的形成，并保持凝集素和经典途径信号通路的正常功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","MEDX","BK0046","BK1574","BMED","MDTX","PSYK","159992","002603","IBBQ","BK0097","BK0188","LNGR","BK0239","06978","IBBJ","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657512105","title":"以岭药业：未来将更加重视现金分红","url":"https://stock-news.laohu8.com/highlight/detail?id=2657512105","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657512105?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:00","pubTimestamp":1785920450,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业08月05日在投资者关系平台上答复投资者关心的问题。公司未来，也将根据实际经营业绩情况，在符合公司利润分配政策、保障公司正常运营和长远发展的前提下，会更加重视现金分红，更好地回报广大股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500030872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0188","BK0046","002603","BK0097"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792036319541,"stockEarnings":[{"period":"1week","weight":-0.0182},{"period":"1month","weight":-0.0202},{"period":"3month","weight":-0.1329},{"period":"6month","weight":-0.0678},{"period":"1year","weight":-0.0025},{"period":"ytd","weight":-0.0885}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0304},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0701},{"period":"1year","weight":-0.0254},{"period":"ytd","weight":-0.0508}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石家庄以岭药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"140038人(较上一季度减少5.38%)","perCapita":"9827股","listingDate":"2011-07-28","address":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","registeredCapital":"167070万元","survey":" 石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是专利中药产品。公司获得了国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。","listedPrice":34.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"以岭药业,002603,以岭药业股票,以岭药业股票老虎,以岭药业股票老虎国际,以岭药业行情,以岭药业股票行情,以岭药业股价,以岭药业股市,以岭药业股票价格,以岭药业股票交易,以岭药业股票购买,以岭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}